$LAB

STANDARD BIOTOOLS INC. (LAB) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific Business will operate as Biomark Scientific, a leader in accessible, scalable and automated genomic workflows powered by proprietary micr

ARCHIMED, a private equity firm, acquired Standard BioTools' Microfluidics Business, renaming it Biomark Scientific. The company specializes in automated genomic workflows and will operate independently under ARCHIMED. Standard BioTools (NASDAQ: LAB) completed the sale, focusing on its core life science tools business.

Standard BioTools (LAB) agreed to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The deal is expected to close in about 30 days, pending customary conditions.

Standard BioTools (NASDAQ: LAB) terminated its agreement to sell its Mass Cytometry business to Multiplex Bio and agreed to sell it to Element Biosystems for $5.5M. The deal increases net cash by $15M for the Treeline merger. Both transactions are expected to close by year-end, pending shareholder approval.

Lab (LAB) fell more than 13% in 24 hours, extending a downtrend, with daily volume up 335% to about $50M and a volume-to-market-cap ratio near 81%, according to the article. It cites technical rejection around $0.15, rising open interest above $124M, exchange hot-wallet selling (KuCoin), and protocol daily revenue dropping from about $191K to about $6.2K.

STANDARD BIOTOOLS INC. (LAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Standard BioTools Reports Second Quarter 2026 Financial Results BOSTON, Mass., August 5, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026. Recent

STANDARD BIOTOOLS INC. (LAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001162194 0001162194 2026-07-24 2026-07-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2026

Genomma Lab Internacional SAB de CV Class B (LAB/B) reported consolidated sales down 6% year over year, citing currency headwinds and softer demand in Mexico and the U.S. Gross margin expanded, lifting net income 5.5%. Latin America grew, and management expects gradual recovery in H2 2026.

The article says LAB token ($LAB) rose about 47% in 24 hours on higher volume and liquidity. It cites a breakout from a descending triangle, with a key resistance range of $0.33 to $0.36, and notes open interest around $129M. It also highlights daily token unlocks of 1.87M LAB (about $355K) and selling pressure from derivatives and CVD.

Labrador Gold Corp. (TSX.V: LAB) says exploration at its Mariposa and Eureka Dome projects in Yukon is underway. It closed the first tranche of a May 8, 2026 option deal with Pacific Ridge Exploration Limited, paying $100,000 and issuing 800,000 shares. Soil sampling is ongoing; an airborne survey was delayed by weather.